Current gene therapy最新文献

筛选
英文 中文
Current Updates on the Role of MicroRNA in the Diagnosis and Treatment of Neurodegenerative Diseases. 微小核糖核酸在神经退行性疾病诊断和治疗中的作用最新进展。
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/0115665232261931231006103234
Ammara Saleem, Maira Javed, Muhammad Furqan Akhtar, Ali Sharif, Bushra Akhtar, Muhammad Naveed, Uzma Saleem, Mirza Muhammad Faran Ashraf Baig, Hafiz Muhammad Zubair, Talha Bin Emran, Mohammad Saleem, Ghulam Md Ashraf
{"title":"Current Updates on the Role of MicroRNA in the Diagnosis and Treatment of Neurodegenerative Diseases.","authors":"Ammara Saleem, Maira Javed, Muhammad Furqan Akhtar, Ali Sharif, Bushra Akhtar, Muhammad Naveed, Uzma Saleem, Mirza Muhammad Faran Ashraf Baig, Hafiz Muhammad Zubair, Talha Bin Emran, Mohammad Saleem, Ghulam Md Ashraf","doi":"10.2174/0115665232261931231006103234","DOIUrl":"10.2174/0115665232261931231006103234","url":null,"abstract":"<p><strong>Background: </strong>MicroRNAs (miRNA) are small noncoding RNAs that play a significant role in the regulation of gene expression. The literature has explored the key involvement of miRNAs in the diagnosis, prognosis, and treatment of various neurodegenerative diseases (NDD), such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). The miRNA regulates various signalling pathways; its dysregulation is involved in the pathogenesis of NDD.</p><p><strong>Objective: </strong>The present review is focused on the involvement of miRNAs in the pathogenesis of NDD and their role in the treatment or management of NDD. The literature provides comprehensive and cutting-edge knowledge for students studying neurology, researchers, clinical psychologists, practitioners, pathologists, and drug development agencies to comprehend the role of miRNAs in the NDD's pathogenesis, regulation of various genes/signalling pathways, such as α-synuclein, P53, amyloid-β, high mobility group protein (HMGB1), and IL-1β, NMDA receptor signalling, cholinergic signalling, etc. Methods: The issues associated with using anti-miRNA therapy are also summarized in this review. The data for this literature were extracted and summarized using various search engines, such as Google Scholar, Pubmed, Scopus, and NCBI using different terms, such as NDD, PD, AD, HD, nanoformulations of mRNA, and role of miRNA in diagnosis and treatment.</p><p><strong>Results: </strong>The miRNAs control various biological actions, such as neuronal differentiation, synaptic plasticity, cytoprotection, neuroinflammation, oxidative stress, apoptosis and chaperone-mediated autophagy, and neurite growth in the central nervous system and diagnosis. Various miRNAs are involved in the regulation of protein aggregation in PD and modulating β-secretase activity in AD. In HD, mutation in the huntingtin (Htt) protein interferes with Ago1 and Ago2, thus affecting the miRNA biogenesis. Currently, many anti-sense technologies are in the research phase for either inhibiting or promoting the activity of miRNA.</p><p><strong>Conclusion: </strong>This review provides new therapeutic approaches and novel biomarkers for the diagnosis and prognosis of NDDs by using miRNA.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"122-134"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification. 宫颈鳞状细胞癌和宫颈内膜腺癌的潜在预后生物标志物 ZNF695 与免疫浸润相关:生物信息学分析和实验验证。
IF 3.8 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/0115665232285216240228071244
Xiaojuan Ding, Ailing Wan, Xin Qi, Ke'er Jiang, Zhao Liu, Buze Chen
{"title":"ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification.","authors":"Xiaojuan Ding, Ailing Wan, Xin Qi, Ke'er Jiang, Zhao Liu, Buze Chen","doi":"10.2174/0115665232285216240228071244","DOIUrl":"10.2174/0115665232285216240228071244","url":null,"abstract":"<p><strong>Background: </strong>The role of Zinc Finger Protein 695 (ZNF695) is unclear in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC).</p><p><strong>Objective: </strong>The objective of this study was to conduct a comprehensive analysis and experimental validation of ZNF695 in CESC.</p><p><strong>Methods: </strong>The study investigated the expression of ZNF695 in both pan-cancer and CESC, utilizing data from The Cancer Genome Atlas (TCGA) database to assess its diagnostic value. The present study investigated the association between ZNF695 expression levels and clinical characteristics, as well as prognosis, in patients with CESC. The study explored potential regulatory networks involving ZNF695, including its association with immune infiltration, immune score, stemness index based on mRNA expression (mRNAsi), and drug sensitivity in CESC. We explored the expression of ZNF695 in CESC single cells. ZNF695 expression was validated using GSE29570.</p><p><strong>Results: </strong>ZNF695 was found to be aberrantly expressed in pan-cancer and CESC. There was a significant correlation observed between an elevated level of ZNF695 expression in patients with CESC and histological grade (p = 0.017). Furthermore, a strong association was found between high ZNF695 expression in CESC patients and poorer overall survival (OS) (HR: 1.87; 95% CI: 1.17-3.00; p = 0.009), Progression-free Survival (PFS) (HR: 1.86; 95% CI: 1.16-2.98; p = 0.010), and Disease-specific Survival (DSS) (HR: 1.98; 95% CI: 1.15-3.42; p = 0.014). The expression of ZNF695 in CESC patients (p = 0.006) was identified as an independent prognostic determinant. ZNF695 was associated with steroid hormone biosynthesis, oxidative phosphorylation, and so on. ZNF695 expression correlated with immune infiltration, immune score, and mRNAsi in CESC. ZNF695 expression significantly and negatively correlated with AICA ribonucleotide, BIX02189, QL-XI-92, STF-62247, and SNX-2112 in CESC. ZNF695 gene was upregulated in CESC tissues and cell lines. ZNF695 was significantly upregulated in the CESC cell lines.</p><p><strong>Conclusion: </strong>ZNF695 may be a potential prognostic biomarker and immunotherapeutic target for CESC patients.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"441-452"},"PeriodicalIF":3.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duchenne Muscular Dystrophy Gene Therapy. 杜兴氏肌肉萎缩症基因疗法。
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/1566523223666221118160932
Fawzy A Saad, Jasen F Saad, Gabriele Siciliano, Luciano Merlini, Corrado Angelini
{"title":"Duchenne Muscular Dystrophy Gene Therapy.","authors":"Fawzy A Saad, Jasen F Saad, Gabriele Siciliano, Luciano Merlini, Corrado Angelini","doi":"10.2174/1566523223666221118160932","DOIUrl":"10.2174/1566523223666221118160932","url":null,"abstract":"<p><p>Duchenne and Becker muscular dystrophies are allelic X-linked recessive neuromuscular diseases affecting both skeletal and cardiac muscles. Therefore, owing to their single X chromosome, the affected boys receive pathogenic gene mutations from their unknowing carrier mothers. Current pharmacological drugs are palliative that address the symptoms of the disease rather than the genetic cause imbedded in the <i>Dystrophin</i> gene DNA sequence. Therefore, alternative therapies like gene drugs that could address the genetic cause of the disease at its root are crucial, which include gene transfer/implantation, exon skipping, and gene editing. Presently, it is possible through genetic reprogramming to engineer AAV vectors to deliver certain therapeutic cargos specifically to muscle or other organs regardless of their serotype. Similarly, it is possible to direct the biogenesis of exosomes to carry gene editing constituents or certain therapeutic cargos to specific tissue or cell type like brain and muscle. While autologous exosomes are immunologically inert, it is possible to camouflage AAV capsids, and lipid nanoparticles to evade the immune system recognition. In this review, we highlight current opportunities for Duchenne muscular dystrophy gene therapy, which has been known thus far as an incurable genetic disease. This article is a part of Gene Therapy of Rare Genetic Diseases thematic issue.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"17-28"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9328449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway. 外显子miR-30a-5p通过调节Notch1/VEGF信号通路调节肾小球内皮细胞的EndMT和血管生成。
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/0115665232258527230919071328
Yaxian Ning, Xiaochun Zhou, Gouqin Wang, Lili Zhang, Jianqin Wang
{"title":"Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway.","authors":"Yaxian Ning, Xiaochun Zhou, Gouqin Wang, Lili Zhang, Jianqin Wang","doi":"10.2174/0115665232258527230919071328","DOIUrl":"10.2174/0115665232258527230919071328","url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy (DN) is one of the microvascular complications of diabetes. Endothelial-mesenchymal transition (EndMT) and endothelial damage lead to abnormal angiogenesis in DN.</p><p><strong>Objectives: </strong>This study aimed to investigate the role of exosome miR-30a-5p in high glucose (HG)-induced glomerular endothelial cells (GECs) dysfunction and explore the underlying mechanisms.</p><p><strong>Methods: </strong>GECs were cultured in normal glucose (5.5 mM) and HG (30 mM) conditions. The recipient GECs were transfected with exosome or miR-30a-5p mimic/inhibitor and then detected by using CCK-8 and flow cytometry assay. Luciferase analysis was used to verify miR-30a-5p acted on notch homolog protein 1 (Notch1). RT-qPCR and Western blot were used to detect the expression of VE-cadherin, α-SMA, vascular endothelial growth factor (VEGF) and Notch1. In vivo, exosome miR-30a-5p was administered to DN mice, and periodic acid-Schiff (PAS) staining, UTP levels, and HbA1c levels were measured.</p><p><strong>Results: </strong>The expression of miR-30a-5p was downregulated in HG-treated GECs. Exosome miR-30a-5p significantly promoted cell proliferation, and migration and reduced apoptosis of GECs under HG conditions. MiR-30a-5p directly targeted the 3-UTR region of Notch1. Exosome miR-30a-5p reduced the expression levels of Notch1 and VEGF, both at mRNA and protein levels. Furthermore, exosome miR-30a-5p inhibited HG-induced EndMT, as evidenced by increased VE-cadherin and reduced α-SMA. In vivo studies demonstrated that exosome miR-30a-5p reduced serum HbA1c levels and 24-hour urine protein quantification.</p><p><strong>Conclusion: </strong>This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"159-177"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene Therapy for Rare Genetic Diseases. 罕见遗传病的基因疗法。
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/1566523223666230320120839
Kenneth Lundstrom, Evangelia Yannaki, Janice Chou, Fawzy A Saad
{"title":"Gene Therapy for Rare Genetic Diseases.","authors":"Kenneth Lundstrom, Evangelia Yannaki, Janice Chou, Fawzy A Saad","doi":"10.2174/1566523223666230320120839","DOIUrl":"10.2174/1566523223666230320120839","url":null,"abstract":"","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"4-5"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9265457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FIGNL1 Promotes Hepatocellular Carcinoma Formation via Remodeling ECM-receptor Interaction Pathway Mediated by HMMR. FIGNL1通过HMMR介导的重塑ECM受体相互作用途径促进肝细胞癌的形成。
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/0115665232274223231017052707
Jiabei Wang, Linmao Sun, Yao Liu, Yunguang Zhang
{"title":"FIGNL1 Promotes Hepatocellular Carcinoma Formation <i>via</i> Remodeling ECM-receptor Interaction Pathway Mediated by HMMR.","authors":"Jiabei Wang, Linmao Sun, Yao Liu, Yunguang Zhang","doi":"10.2174/0115665232274223231017052707","DOIUrl":"10.2174/0115665232274223231017052707","url":null,"abstract":"<p><strong>Background: </strong>The development of novel biomarkers is crucial for the treatment of HCC. In this study, we investigated a new molecular therapeutic target for HCC. Fidgetin-like 1 (FIGNL1) has been reported to play a vital role in lung adenocarcinoma. However, the potential function of FIGNL1 in HCC is still unknown.</p><p><strong>Objective: </strong>This study aims to investigate the key regulatory mechanisms of FIGNL1 in the formation of HCC.</p><p><strong>Methods: </strong>The regulatory effect of FIGNL1 on HCC was studied by lentivirus infection. <i>In vitro</i>, the effects of FIGNL1 on the proliferation, migration and apoptosis of cells were investigated by CCK8, colony formation assay, transwell and flow cytometry. Meanwhile, the regulation of FIGNL1 on HCC formation <i>in vivo</i> was studied by subcutaneous transplanted tumors. In addition, using transcriptome sequencing technology, we further explored the specific molecular mechanism of FIGNL1 regulating the formation of HCC.</p><p><strong>Results: </strong>Functionally, we demonstrated that FIGNL1 knockdown significantly inhibited HCC cell proliferation, migration and promoted cell apoptosis <i>in vitro</i>. Similarly, the knockdown of FIGNL1 meaningfully weakened hepatocarcinogenesis in nude mice. Transcriptome sequencing revealed that FIGNL1 affected the expression of genes involved in extracellular matrix-receptor (ECM-receptor) interaction pathway, such as hyaluronan mediated motility receptor (HMMR). Further validation found that overexpression of HMMR based on knockdown FIGNL1 can rescue the expression abundance of related genes involved in the ECM-receptor interaction pathway.</p><p><strong>Conclusion: </strong>Our study revealed that FIGNL1 could modulate the ECM-receptor interaction pathway through the regulation of HMMR, thus regulating the formation of HCC.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"249-263"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy. 用 AAV 治疗血友病:探索基因疗法的前沿。
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/0115665232279893231228065540
Safir Ullah Khan, Munir Ullah Khan, Muhammad Suleman, Amrah Inam, Muhammad Azhar Ud Din
{"title":"Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy.","authors":"Safir Ullah Khan, Munir Ullah Khan, Muhammad Suleman, Amrah Inam, Muhammad Azhar Ud Din","doi":"10.2174/0115665232279893231228065540","DOIUrl":"10.2174/0115665232279893231228065540","url":null,"abstract":"<p><p>Gene therapy for hemophilia has advanced tremendously after thirty years of continual study and development. Advancements in medical science have facilitated attaining normal levels of Factor VIII (FVIII) or Factor IX (FIX) in individuals with haemophilia, thereby offering the potential for their complete recovery. Despite the notable advancements in various countries, there is significant scope for further enhancement in haemophilia gene therapy. Adeno-associated virus (AAV) currently serves as the primary vehicle for gene therapy in clinical trials targeting haemophilia. Subsequent investigations will prioritize enhancing viral capsid structures, transgene compositions, and promoters to achieve heightened transduction efficacy, diminished immunogenicity, and more predictable therapeutic results. The present study indicates that whereas animal models have transduction efficiency that is over 100% high, human hepatocytes are unable to express clotting factors and transduction efficiency to comparable levels. According to the current study, achieving high transduction efficiency and high levels of clotting factor expression in human hepatocytes is still insufficient. It is also crucial to reduce the risk of cellular stress caused by protein overload. Despite encountering various hurdles, the field of haemophilia gene therapy holds promise for the future. As technology continues to advance and mature, it is anticipated that a personalized therapeutic approach will be developed to cure haemophilia effectively.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"265-277"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Segmentation of Thoracic Organs through Distributed Extraction of Visual Feature Patterns Utilizing Resio-Inception U-Net and Deep Cluster Recognition Techniques. 利用 Resio-Inception U-Net 和深度聚类识别技术,通过分布式提取视觉特征模式分割胸腔脏器
IF 3.6 4区 医学
Current gene therapy Pub Date : 2024-01-01 DOI: 10.2174/0115665232262165231201113932
Karthikeyan Saminathan, Tathagat Banerjee, Devi Priya Rangasamy, Meenalosini Vimal Cruz
{"title":"Segmentation of Thoracic Organs through Distributed Extraction of Visual Feature Patterns Utilizing Resio-Inception U-Net and Deep Cluster Recognition Techniques.","authors":"Karthikeyan Saminathan, Tathagat Banerjee, Devi Priya Rangasamy, Meenalosini Vimal Cruz","doi":"10.2174/0115665232262165231201113932","DOIUrl":"10.2174/0115665232262165231201113932","url":null,"abstract":"<p><strong>Background: </strong>Segmentation of medical images plays a key role in the correct identification and management of different diseases. In this study, we present a new segmentation method that meets the difficulties posed by sophisticated organ shapes in computed tomography (CT) images, particularly targeting lung, breast, and gastric cancers.</p><p><strong>Methods: </strong>Our suggested methods, Resio-Inception U-Net and Deep Cluster Recognition (RIUDCR), use a Residual Inception Architecture, which combines the power of residual connections and inception blocks to achieve cutting-edge segmentation performance while reducing the risk of overfitting.</p><p><strong>Results: </strong>We present mathematical equations and functions that describe the design, including the encoding and decoding steps within the UC-Net system. Furthermore, we provide strong testing results that show the effectiveness of our method. Through thorough testing on varied datasets, our method regularly beats current techniques, achieving amazing precision and stability in organ task segmentation. These results show the promise of our residual inception architecture in better medical picture analysis.</p><p><strong>Conclusion: </strong>In summary, our research not only shows a state-of-the-art segment methodology but also reinforces its usefulness through thorough testing. The inclusion of residual inception architecture in medical picture segmentation offers good possibilities for improving the identification and management of disease planning.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"217-238"},"PeriodicalIF":3.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Splicing DNA Damage Adaptations for the Management of Cancer Cells 剪接DNA损伤对癌细胞管理的适应性
IF 3.6 4区 医学
Current gene therapy Pub Date : 2023-11-29 DOI: 10.2174/0115665232258528231018113410
Arun Kumar Singh, Deepika Yadav, Rishabha Malviya
{"title":"Splicing DNA Damage Adaptations for the Management of Cancer Cells","authors":"Arun Kumar Singh, Deepika Yadav, Rishabha Malviya","doi":"10.2174/0115665232258528231018113410","DOIUrl":"https://doi.org/10.2174/0115665232258528231018113410","url":null,"abstract":": Maintaining a tumour cell's resistance to apoptosis (organized cell death) is essential for cancer to metastasize. Signal molecules play a critical function in the tightly regulated apoptotic process. Apoptosis may be triggered by a wide variety of cellular stresses, including DNA damage, but its ultimate goal is always the same: the removal of damaged cells that might otherwise develop into tumours. Many chemotherapy drugs rely on cancer cells being able to undergo apoptosis as a means of killing them. The mechanisms by which DNA-damaging agents trigger apoptosis, the interplay between pro- and apoptosis-inducing signals, and the potential for alteration of these pathways in cancer are the primary topics of this review.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"7 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138538784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgements to Reviewers 审稿人致谢
4区 医学
Current gene therapy Pub Date : 2023-10-01 DOI: 10.2174/156652322305230816165521
{"title":"Acknowledgements to Reviewers","authors":"","doi":"10.2174/156652322305230816165521","DOIUrl":"https://doi.org/10.2174/156652322305230816165521","url":null,"abstract":"","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135170448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信